证券代码：002382 证券简称：蓝帆医疗 公告编号：2022-082 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 关于参加山东辖区上市公司2022年度投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与广大投资者的互动交流，蓝帆医疗股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会山东监管局及山东上市公司协会联合举办， 深圳市全景网络有限公司（以下简称"全景网"）承办的 "山东辖区上市公司 2022 年 度投资者网上集体接待日"活动，现将有关事项公告如下： 本次投资者网上集体接待日活动将全景网提供的网上平台采取网络远程的方式举 行，投资者可以登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次投资者 集体接待日活动，活动时间为 2022 年 11 月 16 日（星期三）下午 14:00-16:00。 届时公司董事长刘文静女士，董事、总裁钟舒乔先生，副总裁、首席财务官崔运 涛先生，副总裁、董事会秘书兼首席法务官黄婕女士将通过网络在线形式与投资者进 行沟通交 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202203 | --- | --- | --- | --- | |------------------------------|------------------------------------------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------| | | □ 特定对象调研 □ | 分析师会议 | | | | □ 媒体采访 □ | 业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 □ | 路演活动 | | | 类别 | □ 现场参观 ■ 其他 （研发开放日） | | | | | | | 西南证券、前海鸿富基金、高毅资产、兴业基金、信达证券、东方 | | 参与单位名称及 人员姓名 时间 | 国海证券等 17 家机构 2022 年 9 月 9 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202202 | --- | --- | --- | |---------------------------------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 类 ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202204 | --- | --- | --- | |-----------------------------|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------| | | | | | | □ 特定对象调研 □ | 分析师会议 | | | □ 媒体采访 □ | 业绩说明会 | | 投资者关系活动 | □ 新闻发布会 □ | 路演活动 | | 类别 | □ 现场参观 ■ 其他 （电话会议） | | | 参与单位名称及 | 中金基金等 7 家机构投资者 | 信达证券、民生加银、信达澳亚、大成基金、安信基金、万家基金、 | | 人员姓名 | | | | 时间 | 2022 年 10 月 12 日 10 | ： 00-11 ： 00 | | 地点 | ...

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202205 | --- | --- | --- | --- | --- | |---------------------|---------------------------------------------------------|----------------|-----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | □ 特定对象调研 □ | 分析师会议 | | | | 投资者关系活动 | □ 媒体采访 □ | 业绩说明会 | | | | 类别 参与单位名称及 | □ 新闻发布会 □ □ 现场参观 ■ 其他 （电话会议） | 路演活动 | | 信达证券、中金公司、 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥1,181,534,505.69, a decrease of 14.68% compared to the same period last year[6]. - The net profit attributable to shareholders for Q3 2022 was ¥35,721,598.27, an increase of 255.91% year-on-year[6]. - Total operating revenue decreased by 281.72 million yuan, a decline of 42.86% year-on-year, primarily due to a significant drop in product prices despite increased sales volume in the protective division[24]. - Total operating revenue for the current period is approximately $3.76 billion, a decrease of 43% compared to $6.57 billion in the previous period[48]. - Net profit for the current period is approximately -$144.71 million, a significant decline from a net profit of approximately $3.42 billion in the previous period[52]. - The company's total liabilities decreased to approximately $5.19 billion from $6.38 billion in the previous period, reflecting a reduction of about 18.5%[47]. - Total equity attributable to shareholders increased to approximately $10.89 billion from $10.54 billion, marking an increase of about 3.3%[47]. - The company reported a basic earnings per share of -$0.14, down from $3.41 in the previous period[54]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥255,284,295.68, down 89.80% compared to the same period last year[6]. - Net cash flow from operating activities decreased by ¥2,248,119,610.38, down 89.80% year-on-year, primarily due to a reduction in cash received from sales of goods and services[29]. - The net cash flow from investment activities increased by ¥1,933,153,351.07, a growth of 100.22% year-on-year, mainly due to a decrease in cash outflows from investment activities[29]. - The net cash flow from financing activities increased by ¥865,292,517.73, a growth of 91.74% year-on-year, primarily due to a decrease in cash outflows from financing activities[29]. - The net cash flow from financing activities is -¥77,878,992.48, an improvement from -¥943,171,510.21 in the previous period[58]. - The total cash inflow from operating activities is ¥4,572,872,519.96, compared to ¥7,094,474,464.85 in the previous period, indicating a decline[55]. - Cash outflow from operating activities is ¥4,317,588,224.28, slightly reduced from ¥4,591,070,558.79 in the previous period[55]. - The company reported a cash increase of ¥271,074,854.39 for the current period, contrasting with a decrease of -¥430,277,528.98 in the previous period[58]. Assets and Liabilities - The total assets at the end of Q3 2022 were ¥16,076,004,157.87, a decrease of 4.95% from the end of the previous year[6]. - As of September 30, 2022, the total assets of the company amounted to ¥16,076,004,157.87, a decrease from ¥16,913,875,507.52 at the beginning of the year[41]. - The company's current assets totaled ¥4,679,774,966.03, down from ¥6,341,271,206.34 at the start of the year, indicating a decline of approximately 26.2%[44]. - The cash and cash equivalents were reported at ¥2,337,904,523.45, a decrease of 17.6% from ¥2,839,863,972.31 at the beginning of the year[41]. - Inventory decreased to ¥941,431,001.04 from ¥1,124,536,355.21, reflecting a reduction of about 16.2%[44]. - The company's non-current assets increased to ¥11,396,229,191.84 from ¥10,572,604,301.18, representing an increase of approximately 7.8%[44]. - Short-term borrowings rose significantly to ¥142,301,550.94 from ¥12,559,546.52, indicating a substantial increase in leverage[44]. - Total current liabilities decreased to ¥2,204,557,956.88 from ¥3,184,141,878.69, a reduction of about 30.8%[44]. Investment and Income - Investment income increased by ¥215,095,508.60, a growth of 561.24% compared to the same period last year, primarily due to reclassification of accounting for Tongxin Medical[27]. - The company reported a significant increase in investment income to approximately $253.42 million from $38.33 million in the previous period[52]. - Other income increased by ¥7,083,297.66, a growth of 129.28% year-on-year, mainly due to an increase in government subsidies unrelated to daily operations[27]. Division Performance - The cardiovascular division reported a profit of ¥6,353,500 for the first three quarters, driven by a significant investment in high-end medical devices and a shift in accounting treatment for a joint venture[11]. - The sales volume of glove products in the protective division exceeded 24 billion pieces, representing a growth of over 30% year-on-year[14]. - The market share of the company's nitrile gloves in the domestic export market increased from 10.86% in the first three quarters of 2021 to 20.26% in 2022, ranking second nationally[14]. - The nursing division achieved a cumulative profit of 25.75 million yuan in the first three quarters, representing a year-on-year growth of over 50%[15]. - Domestic market revenue for the nursing division grew by over 40% compared to the same period last year[15]. - The emergency kit product line continues to be a key focus, with significant growth potential expected due to capacity expansion projects[15]. Regulatory and Strategic Developments - The company announced the approval of its subsidiary's "U-Mo Coated Coronary Balloon Dilation Catheter" by the NMPA in China, enhancing its product portfolio[40]. - The company has applied for bank credit for its wholly-owned subsidiary, indicating a strategy for financial support and expansion[40]. - The company established partnerships with well-known enterprises such as Didi Chuxing and China Life to provide customized emergency solutions[15]. - The company confirmed share-based payment expenses of ¥34 million related to its core management and technical staff incentive plan[11]. Other Financial Metrics - The weighted average return on equity was 0.33% for Q3 2022, compared to -1.35% for the same period last year[6]. - Other comprehensive income increased by 460.97 million yuan, a growth of 406.29% year-on-year, primarily due to exchange rate fluctuations[19]. - Fair value changes decreased by ¥1,097,283,154.50, a decline of 100.13% year-on-year, mainly due to last year's significant asset restructuring performance compensation[27]. - Asset impairment losses increased by ¥46,552,509.93, a growth of 87.14% year-on-year, primarily due to increased inventory write-down provisions[27].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥2,574,007,108.85, a decrease of 50.39% compared to ¥5,187,983,874.86 in the same period last year[28]. - The net profit attributable to shareholders of the listed company was -¥180,432,657.11, representing a decline of 105.24% from ¥3,441,683,533.55 in the previous year[28]. - The net cash flow from operating activities was ¥225,358,387.82, down 89.40% from ¥2,126,017,555.10 in the same period last year[28]. - Basic earnings per share were -¥0.18, a decrease of 105.33% compared to ¥3.38 in the previous year[28]. - Total assets at the end of the reporting period were ¥15,821,172,126.06, a decrease of 6.46% from ¥16,913,875,507.52 at the end of the previous year[28]. - The net assets attributable to shareholders of the listed company increased by 0.86% to ¥10,626,889,102.88 from ¥10,536,287,382.73 at the end of the previous year[28]. - Total revenue for the reporting period was CNY 2.574 billion, a year-on-year decrease of 50.39%, with a net profit attributable to shareholders of CNY -180.43 million, a decrease of 105.24%[114]. Market and Industry Trends - The global medical device market is projected to grow from approximately $504.3 billion in 2021 to $594.5 billion by 2024, with a compound annual growth rate (CAGR) of 5.6%[39]. - China's medical device market is expected to have an average CAGR of about 14.41% from 2022 to 2026, significantly outpacing global growth rates[42]. - The global emergency kit market was valued at $495 million in 2019 and is projected to reach $744 million by 2026, with a CAGR of 5.90%[47]. Product Development and Innovation - The company is focusing on new product development and market expansion strategies to improve future performance[28]. - The company has established an "A+X" development strategy, focusing on both organic and external growth, covering multiple medical device segments including protective gloves and emergency kits[38]. - The company has launched multiple new products, including the biodegradable drug-eluting coronary stent "Xinkuo" (EXPANSAL) and the polymer-free drug-coated coronary stent "BioFreedom" in various global markets[55]. - The company is actively involved in the development of new products such as the next-generation transcatheter aortic valve replacement system and various balloon catheters[57]. - The company has launched new products including nitrile gloves, latex examination gloves, and surgical gloves, further strengthening its position as the first company in the industry to offer a full range of disposable gloves[60]. Operational Strategies - The company aims to maintain long-term relationships with downstream customers and control operational costs to ensure positive cash flow during market downturns[44]. - The implementation of centralized procurement policies for high-value medical consumables is expected to reshape the industry landscape and accelerate the development of domestic medical device companies[43]. - The company is exploring the feasibility of energy investment plans for its protective and industrial park bases to improve cost efficiency[112]. - The company is committed to providing professional and safe health protection products in the post-pandemic era, aligning with new retail strategies to meet domestic market demands[38]. Competitive Positioning - The company has segmented its business into three divisions: cardiovascular, health protection, and emergency care, focusing on technological innovation for high-quality development[38]. - The cardiovascular business achieved a revenue growth of approximately 110% for the transcatheter aortic valve replacement (TAVR) system in the first half of 2022 compared to the same period last year[54]. - The company sold over 200,000 units of the heart stent product "Xinyue" (EXCROSSAL) in the domestic market, increasing its market share to 23%[54]. - The company's nitrile gloves market share in the domestic export market increased from 9.5% in the first half of 2021 to 20.9% in the first half of 2022[58]. - The protective division sold over 16 billion gloves during the reporting period, representing a growth of over 30% year-on-year, despite a significant drop in product prices post-pandemic[109]. Research and Development - The company has established a global 24-hour R&D system with eight R&D and clinical registration platforms[57]. - The company invested CNY 176 million in R&D, with over 600 patents obtained, emphasizing technology innovation as a core competitive advantage[114]. - The company has built a global 24-hour R&D system with nearly 1,000 technical personnel, ensuring competitive product development through a healthy competition mechanism[122]. - The company has published 26 papers and conducted 8 post-market clinical trials for its innovative heart valve products, demonstrating a strong commitment to research and development[127]. Environmental and Social Responsibility - The company is actively pursuing green factory and energy management system certifications to achieve low-carbon production[59]. - The company will enhance environmental governance by increasing investment in environmental protection and improving production technology, ensuring compliance with environmental standards[195]. - The company is committed to promoting AED devices across the country, having won a bid for 2,000 AED units for the Zibo government project[121]. Future Outlook - The company plans to optimize its market layout by expanding into emerging markets and diversifying its consumer base, targeting C-end, B-end, and G-end markets[197]. - The company will closely monitor exchange rate fluctuations and utilize hedging tools to mitigate adverse impacts on business operations[197]. - The company aims to improve production efficiency and reduce costs by enhancing production processes and automation levels, which is crucial for long-term competitiveness[195].

Business Focus and Strategy - The company reported a significant shift in its main business focus from health protection to include medical devices and nursing services [25]. - The company has redefined its strategy to focus on "new medical + big health," aiming for high-quality and innovative development across its business segments [54]. - The company is focused on domestic market expansion while pursuing international development, aligning with national strategies for dual circulation [97]. - The company aims to build a dual industry platform of "health protection + medical health" over the next 3-5 years, leveraging both domestic and international synergies [105]. - The company is actively developing new channels, markets, and products to meet domestic market demands while expanding its international presence [67]. Financial Performance - The company's operating revenue for 2021 was ¥8,108,586,464.73, representing a 3.04% increase compared to ¥7,869,425,144.32 in 2020 [27]. - The net profit attributable to shareholders for 2021 was ¥1,155,709,191.19, a decrease of 34.28% from ¥1,758,477,255.29 in 2020 [27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥62,125,153.70, down 96.43% from ¥1,741,826,559.80 in 2020 [27]. - Total revenue for the company in 2021 was CNY 8.11 billion, representing a year-on-year growth of 3.04% [86]. - The company's net profit from health protection products reached CNY 2.492 billion in 2021, despite a significant decline in product prices starting from Q2 2021 [80]. Investments and Capital Expenditure - The company signed a long-term loan agreement with the International Finance Corporation for €50 million to support the construction of nitrile glove production capacity [43]. - The company invested CNY 155 million in Nanjing Wofuman Medical Technology to enhance its vascular imaging system and expand its cardiovascular product line [49]. - The company is currently working on a project to produce 100 billion high-end health protection gloves annually, with an investment of ¥1,555,799,550.01, which is 80% complete [164]. - The company has permanently supplemented working capital with CNY 27,852.73 million of surplus raised funds [187]. Research and Development - The company increased its R&D investment to CNY 518.21 million in 2021, resulting in over 550 patented technologies [86]. - The total R&D investment for 2021 was ¥518,213,659.62, up 49.47% from ¥346,689,295.87 in 2020 [138]. - The company completed several key R&D projects, including the development of various types of medical gloves and a drug-coated coronary stent system, which are now ready for market [135]. - The company has established a global R&D system with eight platforms across various countries, employing over a thousand R&D personnel and holding more than 550 patents [99]. Market Position and Product Development - The company is a leader in the drug-eluting stent market, with proprietary products like the Biolimus A9TM and the BioFreedomTM stent, which is the only drug-eluting stent approved for high-bleeding-risk patients in China [47]. - The cardiovascular division of the company benefits from a rapidly growing medical device market in China, projected to reach CNY 833.6 billion by 2021, with a CAGR of 19.8% from 2016 to 2019 [44]. - The company has launched several production projects, including a 200 million pairs/year surgical glove project and a 7.5 billion pairs/year nitrile glove project, enhancing its product line and capacity to meet customer demand [56]. - The company has built an integrated medical device platform covering low, medium, and high-value consumables, effectively mitigating cyclical and business model risks [93]. Sales and Revenue Distribution - Revenue from health protection products was ¥7,354,175,653.82, accounting for 90.70% of total revenue, with an 8.91% increase from ¥6,752,711,258.22 in 2020 [115]. - Cardiovascular products revenue decreased by 28.01% to ¥709,823,758.93 from ¥986,060,952.73 in 2020, representing 8.75% of total revenue [115]. - Domestic revenue fell significantly by 58.65% to ¥758,938,220.45, while overseas revenue increased by 21.81% to ¥7,349,648,244.28, making up 90.64% of total revenue [115]. - The sales model for the protective division primarily focuses on overseas sales, with a significant portion of revenue generated from international markets [74]. Operational Efficiency and Manufacturing - The company has implemented advanced manufacturing technologies, including smart sensors and collaborative robots, to improve production efficiency and reduce costs [55]. - The cardiovascular division employs a semi-automated production process for heart stents, ensuring product reliability and quality stability through a comprehensive quality management system [72]. - The company aims to build an intelligent and lean smart factory, leveraging national strategic opportunities from the Yangtze River Economic Belt and the rise of central China [67]. Challenges and Risks - The health protection sector has a large market space and rigid demand, but faces challenges such as low entry barriers and potential oversupply leading to price declines [8]. - The cardiovascular division reported a loss of CNY 737 million in 2021 due to the impact of domestic procurement policies and ongoing pandemic challenges [81]. - The company emphasizes the importance of risk awareness among investors regarding future plans and performance forecasts [6].

蓝帆医疗股份有限公司 2021 年年度报告全文 蓝帆医疗股份有限公司 BLUE SAIL MEDICAL CO.,LTD. （山东省淄博市齐鲁化学工业区清田路 21 号） 二〇二一年年度报告 股票代码：002382 二〇二二年四月 1 蓝帆医疗股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人刘文静、主管会计工作负责人孙传志及会计机构负责人(会计主 管人员)孙传志声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告中涉及未来的计划、经营目标、业绩预测等方面的内容，均不 构成本公司对任何投资者的实质承诺，投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异，敬请广大的投资者注 意投资风险。 本年度报告第三节"管理层讨论与分析"章节中详细描述了公司可能面对的 风险，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以实施权益分派股权 ...

蓝帆医疗股份有限公司 2022 年第一季度报告全文 □ 是 √ 否 证券代码：002382 证券简称：蓝帆医疗 公告编号：2022-036 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 2022年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 本报告期 上年同期 本报告期比上年同期增减 | --- | --- | --- | --- | |-----------------------------------------------------|-------------------|----------------- ...